Kenvue price target lowered to $23 from $25 at Evercore ISI

Evercore ISI lowered the firm’s price target on Kenvue (KVUE) to $23 from $25 and keeps an In Line rating on the shares. The firm’s price target has been adjusted downward to reflect lower peer valuations and the premium Tylenol commands within Kenvue’s portfolio, but the analyst added that the recent selloff in shares “might be overdone” when considering the lack of a proven causal link between Tylenol’s active ingredient and neurodevelopmental disorders. Despite headline risks, a lack of definitive evidence linking acetaminophen to autism may suggest limited long-term impact, but legal uncertainties could delay strategic moves, the analyst added.